title: The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
abstract: OBJECTIVE
  We aimed to assess the efficacy of abatacept in Japanese patients with rheumatoid arthritis (RA) in clinical practice.
  
  
  METHODS
  We examined 92 patients who received abatacept for 104 weeks. Analysis of radiographic efficacy was conducted using van der Heijde-modified total Sharp score (mTSS). Disease activity score was assessed using disease activity score in 28 joints (DAS28) and simplified disease activity index (SDAI) by last observation carried forward.
  
  
  RESULTS
  The change in mTSS was 0.61 at 52 weeks and 0.27 at 52-104 weeks. Structural remission occurred in 64.9% at 52 weeks and 76.6% at 104 weeks. The significant risk factors for joint damage progression at 52 weeks were prednisolone use, baseline C-reactive protein level (CRP), and erythrocyte sedimentation rate (ESR), as well as average DAS28-CRP and DAS28-ESR scores, SDAI, CRP, ESR, and matrix metalloproteinase-3 (MMP-3) levels. The clinical remission rates were 47.8% by DAS28-CRP, 39.1% by DAS28-ESR, and 30.4% by SDAI at 52 weeks, were 59.8% by DAS28-CRP, 48.9% by DAS28-ESR, and 43.5% by SDAI at 104 weeks.
  
  
  CONCLUSIONS
  This study suggested efficacy of abatacept treatment in Japanese patient with RA for 104 weeks in daily clinical practice. Abatacept lead to suppress joint destruction for 104 weeks.
authors.affiliation: a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan .
authors.forename: Takeshi
authors.initials: T
authors.lastname: Mochizuki
authors.affiliation: b Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan , and.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yano
authors.affiliation: b Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan , and.
authors.forename: Katsunori
authors.initials: K
authors.lastname: Ikari
authors.affiliation: a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan .
authors.forename: Ryo
authors.initials: R
authors.lastname: Hiroshima
authors.affiliation: a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan .
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Takaoka
authors.affiliation: a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan .
authors.forename: Kosei
authors.initials: K
authors.lastname: Kawakami
authors.affiliation: a Department of Orthopedic Surgery , Kamagaya General Hospital , Kamagaya , Japan .
authors.forename: Naoko
authors.initials: N
authors.lastname: Koenuma
authors.affiliation: c Department of Orthopedic Surgery , Chibanishi General Hospital , Chiba , Japan.
authors.forename: Toshikatsu
authors.initials: T
authors.lastname: Shirahata
authors.affiliation: b Institute of Rheumatology, Tokyo Women's Medical University , Tokyo , Japan , and.
authors.forename: Shigeki
authors.initials: S
authors.lastname: Momohara
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use*; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000097:blood; D008875:Middle Aged; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D000069594:Abatacept; D002097:C-Reactive Protein; C511768:MMP3 protein, human; D019278:Matrix Metalloproteinase 3
keywords: Abatacept; Modified total sharp score; Rheumatoid arthritis; Structural remission